Bone Abstracts

Children with chronic gastroduodenitis (CGD) have decreased absorption of nutrients, minerals particularly, which can influence on bone strength and linear growth.Objectives: We evaluated bone mineral density (BMD) in children with CGD and compared with healthy individuals.Methods: BMD was measured in 97 children aged 5–13 years by lumbar spine DXA (DPX MD+, Lunar) with pediatric reference database. BMD was evaluated according...

Objectives: Juvenile idiopathic arthritis (JIA) – is a chronic inflammatory disease of joints which can affect optimal linear growth, risk of fractures and bone quality during the childhood and adult life. The aim of our study was to detect the simple clinical and laboratorial markers which can predict the realization of low bone mineral density (LBMD <−2 S.D.) in children with JIA.Methods: 198 children (82 boys and 116 girl...

Objectives: The purpose of our study was to evaluate the bone mineral accrual in children with osteogenesis imperfecta (OI) treated by pamidronate (PAM).Methods: In retrospective study 43 children with different types of OI were included: 17 boys (39.5%) and 26 girls (60.5%). According to clinical OI, patients were: OI I type -13 (30.2%), OI III type – 24 (55.9%) OI IV type – 4 (9.3%), OI V type 1 (2.3%) and Bruck syndrome 1 (2.3%). The standar...

Objectives: Chronic non-bacterial osteomyelitis (CNO) is a heterogenic group of immune-mediated inflammatory bone diseases with unclear pathogenesis. Only a few genes associated with this condition have identified. The aim of the study was to evaluate the spectrum of mutations in genes associated with primary immunodeficiency syndromes (PIDs) and autoinflammatory diseases (AIDs) in the cohort of patients with early-onset CNO from North Caucasus (Dagestan and Chechnya) and asse...

Objectives: We evaluated the efficacy and safety of intravenous zoledronic acid (IV ZA) in children with glucocorticoid-induced osteoporosis (GIOP) through a randomized, placebo (PBO)-controlled trial.Methods: In this multi-national Phase 3 trial (NCT00799266), children 5–17 years of age with GIOP and low-trauma vertebral fractures (VF) were randomized 1:1 to IV ZA 0.05 mg/kg or IV PBO every six months for one year. Changes in lumbar spine areal bon...